Table 3:
Toxicity Monitoring (N= 39)
| Adverse Event | Grade | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | ||||||
| N | % | N | % | N | % | N | % | ||
| Type | Arm | ||||||||
| Nausea | Poly-E | 2 | 10.5 | ||||||
| Abdominal pain | Placebo | 1 | 5.03 | ||||||
| ALT1 increase | Poly-E | 13 | 5.3 | ||||||
| AST2 increase | Poly-E | 13 | 5.3 | ||||||
| Diarrhea | Poly-E | 1 | 5.3 | ||||||
| Dizziness | Placebo | 1 | 5.0 | ||||||
| Dyspepsia | Placebo | 1 | 5.03 | ||||||
| Fatigue | Placebo | 1 | 5.0 | ||||||
| Flu-like syndrome | Placebo | 1 | 5.0 | ||||||
| Headache | Placebo | 1 | 5.0 | ||||||
| Myalgia | Placebo | 1 | 5.0 | ||||||
Alanine aminotransferase
Aspartate aminotransferase;
same patient